Century Therapeutics (IPSC) Operating Income (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Operating Income data on file, last reported at -$23.7 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$23.7 million, down 131.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$99.9 million (down 225.91% YoY), and the FY2025 annual result was -$2.0 million, up 92.25% from the prior year.
• Operating Income eased to -$23.7 million in Q1 2026 per IPSC's latest filing, from -$5.4 million in the prior quarter.
• Over five years, Operating Income peaked at $74.7 million in Q4 2024 and troughed at -$43.8 million in Q4 2023.
• A 5-year average of -$19.5 million and a median of -$33.3 million in 2022 frame the typical range for Operating Income.
• The sharpest annual moves came in 2025 and 2026: Operating Income soared 336.92% in 2025, then sank 131.93% in 2026.
• A 5-year view of Operating Income shows it stood at -$33.3 million in 2022, then plunged by 31.39% to -$43.8 million in 2023, then jumped by 270.68% to $74.7 million in 2024, then slumped by 107.24% to -$5.4 million in 2025, then plunged by 337.94% to -$23.7 million in 2026.
• Business Quant data shows IPSC's Operating Income at -$23.7 million in Q1 2026, -$5.4 million in Q4 2025, and -$36.1 million in Q3 2025.